Highly galactosylated anti-tnf-alpha antibodies and uses thereof

Abstract

In one aspect, the disclosure relates to highly galactosylated anti-TNF-alpha antibodies and compositions thereof. In one aspect, the disclosure relates to populations of anti-TNF-alpha antibodies with a high level of galactosylation, and compositions thereof. In one aspect, the disclosure relates to methods of production and use of highly galactosylated anti-TNF-alpha antibodies and populations of anti-TNF-alpha antibodies with a high level of galactosylation. In some embodiments, the anti-TNF-alpha antibody is adalimumab.

What is claimed is: 
     
         1 - 77 . (canceled) 
     
     
         78 . A composition, comprising a population of antibodies,
 wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal;   wherein the level of galactosylation of the antibodies in the population of antibodies comprises at least 5% mono-galactosylated N-glycans or at least 10% bigalactosylated N-glycans;   wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and   wherein the antibodies in the population of antibodies comprise a heavy chain (HC), which comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) 100% identical to HC CDR1, HC CDR2 and HC CDR3 of SEQ ID NO: 1 and a light chain (LC), which comprises a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) 100% identical to LC CDR1, LC CDR2 and LC CDR3 of SEQ ID NO: 2.   
     
     
         79 . The composition of  claim 78 , wherein at least 25% of the antibodies in the population comprise mono-galactosylated N-glycans and at least 35% of the antibodies in the population comprise bi-galactosylated N-glycans. 
     
     
         80 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is at least 40%. 
     
     
         81 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is 30.4%-78.2%. 
     
     
         82 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is at least 50%. 
     
     
         83 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is at least 60%. 
     
     
         84 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is at least 70%. 
     
     
         85 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is at least 80%. 
     
     
         86 . The composition of  claim 78 , wherein the level of fucosylation of the antibodies in the population is at least 90%. 
     
     
         87 . The composition of  claim 78 , wherein the ratio of the level of galactosylation of the antibodies in the population to the level of fucosylation of the antibodies in the population is between 1.0 and 1.4. 
     
     
         88 . The composition of  claim 78 , wherein the population of antibodies has an increased level of complement dependent cytotoxicity (CDC) activity when compared to a population of antibodies not produced in mammary gland epithelial cells. 
     
     
         89 . The composition of  claim 78 , wherein the population of antibodies has an increased level of antibody-dependent cellular cytotoxicity (ADCC) activity when compared to a population of antibodies not produced in mammary gland epithelial cells. 
     
     
         90 . The composition of  claim 78 , wherein the transgenic non-human mammal is a goat, sheep, camel, cow, pig, rabbit, rat, mouse or llama. 
     
     
         91 . The composition of  claim 90 , wherein the transgenic non-human mammal is a goat. 
     
     
         92 . A composition, comprising: a population of antibodies,
 wherein the antibodies in the population of antibodies are anti-TNF-alpha antibodies produced in mammary gland epithelial cells of a transgenic non-human mammal;   wherein at least 30% of the antibodies in the population of antibodies contain at least one oligomannose;   wherein the level of fucosylation of the antibodies in the population of antibodies is at least 30%; and   wherein the antibodies in the population of antibodies comprise a heavy chain (HC), which comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) 100% identical to HC CDR1, HC CDR2 and HC CDR3 of SEQ ID NO: 1 and a light chain (LC), which comprises a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) 100% identical to LC CDR1, LC CDR2 and LC CDR3 of SEQ ID NO: 2.   
     
     
         93 . The composition of  claim 92 , wherein the antibodies in the population of antibodies exhibit a high mannose glycosylation pattern. 
     
     
         94 . The composition of  claim 93 , wherein at least one chain of the antibodies in the population of antibodies contains an oligomannose and is non-fucosylated. 
     
     
         95 . The composition of  claim 92 , wherein the major carbohydrate of the antibodies in the population of antibodies is non-fucosylated. 
     
     
         96 . The composition of  claim 92 , wherein the transgenic non-human mammal is a goat, sheep, camel, cow, pig, rabbit, rat, mouse or llama. 
     
     
         97 . The composition of  claim 96 , wherein the transgenic non-human mammal is a goat.